Slovenian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
ovarian neoplasms/tyrosine
Povezava se shrani v odložišče
Stran 1 iz 37 rezultatov
Immunophenotyping and Xist Gene in AML
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by clonal expansion of myeloid progenitors (blasts) in the bone marrow and peripheral blood. with high mortality and variable prognosis. AML is the most common acute leukemia in adults, accounting for ~ 80 percent of cases in
Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Ovarian cancer (OC) is the seventh most common cancer and the fifth cause of cancer death in women worldwide. The most frequent type is surface epithelial tumors. It is frequently diagnosed at advanced stages. So, it is referred to as silent killer.
Serous carcinoma is the most common and aggressive
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
With the development of cost effective and rapid technology of genome sequencing, precision medicine becomes a new way to think oncology. Current targets involve mainly tyrosine kinase, but DNA repair machinery could also be targetable. Some of DNA repair aberrations have been associated with
Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
This is a retrospective cohort with collection of tissues samples (FFPE or frozen), including female patients >18-year-old treated in French between 2009 and 2016 for a thyroid carcinoma on struma ovarii. Clinical data and tissues will be centralized for assessment. One of the endpoint is the
Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Ovarian cancer is the leading cause of death for patients with gynecologic malignancies. In most cases, the disease is diagnosed at an advanced stage and approximately 75% of patients will eventually experience disease recurrence. However, the overall response rates of second-line chemotherapy for
Sub-type Specific Genomic Mutations in sBOTs
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Introduction Borderline Ovarian Tumors (BOTs) behave indolently in the vast majority of cases and the prognosis is usually favorable. There is more evidence that two subtypes of BOTs represent a higher risk of recurrence or even progression to an invasive ovarian cancer. In case of a presentation
Assessing the Immunogenicity of pING-hHER3FL
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
The human epidermal growth factor receptor (HER) family including HER1 (also known as EGFR), HER2, HER3 and HER4 (also known as ErbB2, ErbB3, and ErbB4 respectively) is an important receptor family for the development of many malignancies. HER3 is overexpressed in breast, lung, gastric, head and
Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
The overall 5-year survival rate of ovarian cancer is 45%. The mortality rate of ovarian cancer accounts for the first in gynecologic cancer deaths. Ovarian cytoreductive surgery and postoperative platinum based chemotherapy are the standard treatment for advanced ovarian cancer. About 80% of
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Bladder cancer is the 9th most common cancer worldwide, with around 429.800 new cases diagnosed in 2012 and the 5th most common cancer in Europe, with more than 151.000 new cases diagnosed in 2012. Relating mortality figures, bladder cancer is the 13th most common cause of cancer death worldwide,
A Study of Apatinib Treatment in for Advanced Ovarian Cancer
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Ovarian cancer and fallopian tube cancer are common gynecological malignancies in our country. Ovarian cancer ranks the second in the incidence of gynecologic malignancies. The mortality rate is the highest. The following three major characteristics exist: First, 70% of the patients are advanced
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Ovarian cancer is the leading cause of death for patients with gynecologic malignancies. In most cases, the disease is diagnosed at an advanced stage and approximately 75% of patients will eventually experience disease recurrence. However, the overall response rates of second-line chemotherapy for
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
This is a phase 1a / 1b, first-in-human, open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamic study of TP-0903 administered once daily for the first 21 out of 28 days.
There are 2 phases in this study. In Phase 1a (dose escalation), sequential cohorts of three (3) patients will
Najbolj popolna baza zdravilnih zelišč, podprta z znanostjo
- Deluje v 55 jezikih
- Zeliščna zdravila, podprta z znanostjo
- Prepoznavanje zelišč po sliki
- Interaktivni GPS zemljevid - označite zelišča na lokaciji (kmalu)
- Preberite znanstvene publikacije, povezane z vašim iskanjem
- Iščite zdravilna zelišča po njihovih učinkih
- Organizirajte svoje interese in bodite na tekočem z raziskavami novic, kliničnimi preskušanji in patenti
Vnesite simptom ali bolezen in preberite o zeliščih, ki bi lahko pomagala, vnesite zelišče in si oglejte bolezni in simptome, proti katerim se uporablja.
* Vse informacije temeljijo na objavljenih znanstvenih raziskavah
